The deal is on track with regulatory clearance obtained. The key remaining catalyst is the shareholder vote. Monitor for any competing bids or significant shareholder dissent that could delay or alter terms. The CVR provides optionality on ampreloxetine, but its value is highly speculative and dependent on Zymeworks' actions.
Price Chart
Executive Summary
Theravance Biopharma (TBPH) filed a preliminary proxy statement (PREM14A) for an extraordinary general meeting to approve its acquisition by Zymeworks Inc. (ZYME) for $17.00 per share in cash plus one non-tradable contingent value right (CVR) per share tied to future monetization of ampreloxetine. The all-cash deal values TBPH at approximately $928M equity value, with the board unanimously recommending approval. The HSR waiting period has been terminated early, and the deal is expected to close in H2 2026, subject to shareholder vote and other customary conditions.
Key Financial Metrics
Key Facts
- TBPH shareholders to receive $17.00 per share in cash plus one CVR per share.
- CVR provides 80% of net proceeds from any ampreloxetine monetization within 10 years, a $50M milestone on first commercial sale, and 10% royalties on net sales.
- Theravance Biopharma board unanimously recommends voting FOR the merger.
- HSR Act waiting period terminated early on August 4, 2026.
- Zymeworks has secured a $350M debt commitment from OMERS Life Sciences; no financing condition.
- Lazard rendered a fairness opinion that the $17.00 per share plus CVR is fair from a financial point of view.
- Termination fee of $32,515,000 payable by either party under specified circumstances.
- Shareholder vote requires approval of at least two-thirds of shares present and voting.
- Dissenters' rights available under Cayman Islands law.
- Proposed maximum aggregate transaction value is $928,265,233.23.
Financial Impact
All-cash consideration of $17.00 per share values TBPH at approximately $928M equity value. CVR provides contingent upside tied to ampreloxetine monetization, with a $50M milestone and 10% royalties.
Risk Factors
- Shareholder vote may not be obtained.
- CVR payments are highly speculative and may never materialize.
- Potential litigation challenging the merger.
- Execution risk related to Zymeworks' financing and integration.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| PREM14A Filing (TBPH) — Batch item 1 | 0001104659-26-093784 |
| Document: tm2621435d1_ex-filingfees.htm | 0001104659-26-093784 |
| Document: 0001104659-26-093784-index-headers.html | 0001104659-26-093784 |
| Document: 0001104659-26-093784-index.html | 0001104659-26-093784 |
| Document: 0001104659-26-093784.txt | 0001104659-26-093784 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 25, 2026 5w ago | DEFA14A | $17.03 $17.03 | · 0.00% | ▼ −0.23% | — |
Aug 21, 2026 6w ago | DEFM14A | $17.01 $17.05 | ▲ +0.24% | ▲ +0.76% | — |
Aug 11, 2026 7w ago | PREM14A | $16.91 $17.06 | ▲ +0.89% | ▲ +1.95% | — |
Aug 10, 2026 7w ago | 8-K | $16.91 $17.06 | ▲ +0.89% | ▲ +1.80% | — |
Jun 29, 2026 13w ago | 8-K | $17.06 $16.86 | ▼ −1.17% | ▼ −0.89% | — |
Jun 23, 2026 14w ago | 8-K | $17.27 $16.81 | ▼ −2.66% | ▼ −4.60% | — |
May 7, 2026 21w ago | 8-K | $17.02 $15.92 | ▼ −6.46% | ▼ −9.60% | — |
Mar 3, 2026 30w ago | 8-K | $13.96 $16.23 | ▼ −16.26% | ▼ −20.66% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access